Vertex Pharmaceuticals (VRTX) Gets a Hold Rating from Maxim Group

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Vertex Pharmaceuticals (VRTXResearch Report). The company’s shares closed last Friday at $201.58, close to its 52-week low of $185.33.

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 25.4% and a 33.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, SELLAS Life Sciences Group, and Lineage Cell Therapeutics.

Vertex Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $262.36, implying a 30.2% upside from current levels. In a report released yesterday, Needham also assigned a Hold rating to the stock.

See today’s analyst top recommended stocks >>

Vertex Pharmaceuticals’ market cap is currently $52.18B and has a P/E ratio of 19.10. The company has a Price to Book ratio of 6.84.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.